Be. Akpunonu et al., SUBCUTANEOUS SUMATRIPTAN FOR TREATMENT OF ACUTE MIGRAINE IN PATIENTS ADMITTED TO THE EMERGENCY DEPARTMENT - A MULTICENTER STUDY, Annals of emergency medicine, 25(4), 1995, pp. 464-469
Study objective: To assess the efficacy of SC sumatriptan injection ve
rsus placebo in the treatment of acute migraine in ED patients and tha
t of open-label 100 mg sumatriptan PO tablets for recurrent migraine.
Design: Randomized, double-blind, placebo-controlled, multi-centertria
l. Setting: Twelve EDs in the United States. Participants: Adult patie
nts presenting to the ED from September 1992 through April 1993 with a
diagnosis of migraine as determined by International Headache Society
criteria. Patients were randomized to receive 6 mg sumatriptan SC or
placebo. Patients were monitored for improvement in headache severity
using a four-point scale and for time to meaningful relief using a sto
pwatch. The time to discharge from the ED was recorded. An open-label
100 mg sumatriptan PO tablet was given to all patients on discharge fr
om the ED for use at home if the headache recurred within 24 hours. Re
sults: One hundred thirty-six patients were enrolled. Seventy five per
cent of patients treated with sumatriptan achieved meaningful relief c
ompared with 35% treated with placebo (P<.001). The median time to mea
ningful relief was 34 minutes in the group that received sumatriptan.
Seventy percent of patients in the sumatriptan group versus 35% in the
placebo group reported mild or no pain at discharge (P<.001). Migrain
e-associated symptoms such as nausea, photophobia, and phonophobia wer
e significantly reduced in the sumatriptan group (P<.005). The median
time to discharge from the ED was shorter for the sumatriptan group th
an for the placebo group (60 versus 96 minutes, respectively; P=.001).
At baseline, 15% of patients in the sumatriptan group and 19% of pati
ents in the placebo group reported mild or no clinical disability. At
the time of discharge, patients with mild or no disability increased t
o 75% in the sumatriptan group compared with 44% in the placebo group
(P=.001). Fifty-seven of 92 patients (62%) with mild or no pain at dis
charge took open-label oral sumatriptan for headache recurrence, and 3
7 (65%) experi enced meaningful relief within 2 hours. Median time to
meaningful relief after oral sumatriptan was 65 minutes.Conclusion: Su
matriptan (6 mg SC) is effective in treating acute migraine in the ED.
Oral sumatriptan (100 mg) is effective in treating headache recurrenc
e within 24 hours.